Asset Details
Do you wish to reserve the book?
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Do you wish to request the book?
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cannabinoid treatment for autism: a proof-of-concept randomized trial
2021
Overview
Background
Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD.
Methods
We tested (1) BOL-DP-O-01-W, a whole-plant cannabis extract containing cannabidiol and Δ9-tetrahydrocannabinol at a 20:1 ratio and (2) BOL-DP-O-01, purified cannabidiol and Δ9-tetrahydrocannabinol at the same ratio. Participants (
N
= 150) received either placebo or cannabinoids for 12-weeks (testing efficacy) followed by a 4-week washout and predetermined cross-over for another 12 weeks to further assess tolerability.
Registered primary efficacy outcome measures were improvement in behavioral problems (differences between whole-plant extract and placebo) on the Home Situation Questionnaire-ASD (HSQ-ASD) and the Clinical Global Impression-Improvement scale with disruptive behavior anchor points (CGI-I). Secondary measures were Social Responsiveness Scale (SRS-2) and Autism Parenting Stress Index (APSI).
Results
Changes in Total Scores of HSQ-ASD (primary-outcome) and APSI (secondary-outcome) did not differ among groups. Disruptive behavior on the CGI-I (co-primary outcome) was either much or very much improved in 49% on whole-plant extract (
n
= 45) versus 21% on placebo (
n
= 47;
p
= 0.005). Median SRS Total Score (secondary-outcome) improved by 14.9 on whole-plant extract (
n
= 34) versus 3.6 points after placebo (
n
= 36);
p
= 0.009). There were no treatment-related serious adverse events. Common adverse events included somnolence and decreased appetite, reported for 28% and 25% on whole-plant extract, respectively (
n
= 95); 23% and 21% on pure-cannabinoids (
n
= 93), and 8% and 15% on placebo (
n
= 94).
Limitations
Lack of pharmacokinetic data and a wide range of ages and functional levels among participants warrant caution when interpreting the results.
Conclusions
This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended.
Trial registration
ClinicalTrials.gov: NCT02956226. Registered 06 November 2016,
https://clinicaltrials.gov/ct2/show/NCT02956226
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
